| 000 | 01846 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515090207.0 | ||
| 264 | 0 | _c20071228 | |
| 008 | 200712s 0 0 eng d | ||
| 022 | _a1075-2765 | ||
| 024 | 7 |
_a10.1097/01.mjt.0000212899.58575.33 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAbiose, Ademola K | |
| 245 | 0 | 0 |
_aIncreased vascular alpha1-adrenergic sensitivity in patients with renal failure: receiving recombinant erythropoeitin. _h[electronic resource] |
| 260 |
_bAmerican journal of therapeutics _c |
||
| 300 |
_a427-34 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBradykinin _xpharmacology |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aErythropoietin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHand |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xetiology |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xphysiopathology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNitric Oxide _xmetabolism |
| 650 | 0 | 4 |
_aPhenylephrine _xadministration & dosage |
| 650 | 0 | 4 |
_aReceptors, Adrenergic, alpha-1 _xdrug effects |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aRenal Dialysis |
| 650 | 0 | 4 |
_aVascular Resistance _xdrug effects |
| 650 | 0 | 4 |
_aVasoconstrictor Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aVasodilator Agents _xpharmacology |
| 650 | 0 | 4 |
_aVeins _xdrug effects |
| 700 | 1 | _aAronow, Wilbert S | |
| 700 | 1 | _aMoreno, Heitor | |
| 700 | 1 | _aNair, Chandra K | |
| 700 | 1 | _aBlaschke, Terrence F | |
| 700 | 1 | _aHoffman, Brian B | |
| 773 | 0 |
_tAmerican journal of therapeutics _gvol. 14 _gno. 5 _gp. 427-34 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/01.mjt.0000212899.58575.33 _zAvailable from publisher's website |
| 999 |
_c17413949 _d17413949 |
||